ImmuPharma plc (LON:IMM – Get Free Report) shot up 86.7% on Thursday . The stock traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.24 ($0.03). 12,117,709 shares traded hands during mid-day trading, an increase of 314% from the average session volume of 2,929,006 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Price Performance
The firm has a market cap of £8.75 million, a price-to-earnings ratio of -210.00 and a beta of 1.53. The business has a 50-day moving average of GBX 1.36 and a 200-day moving average of GBX 1.63.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Further Reading
- Five stocks we like better than ImmuPharma
- What is Insider Trading? What You Can Learn from Insider Trading
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
